SHROOM2 and breast cancer: This study utilized transcriptomic data from The Cancer Genome Atlas (TCGA) to assess SHROOM2 expression across various cancers, investigating its correlations with prognosis, clinicopathological features, TMB, and immune characteristics in pan-cancer, with a specific focus on BC.